Vical Inc (NASDAQ:VICL)
| 3.50 Data as of May 24 |  -0.08 / -2.23%Today’s Change | 2.61 Today|||52-Week Range 4.74 | +20.27% Year-to-Date |
Latest VICL News | Press Releases
| Interesting VICL Put And Call For July May 20 / TheStreet.com |
Today’s Trading
| Previous close | 3.58 |
| Today’s open | 3.55 |
| Day’s range | 3.49 - 3.61 |
| Volume | 455,394 |
| Average volume (3 months) | 660,627 |
| Market cap | $302.6M |
| Dividend yield | -- |
Data as of 4:00pm ET, 05/24/2013
Growth & Valuation
| Earnings growth (last year) | -170.00% |
| Earnings growth (this year) | -71.43% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -41.64% |
| P/E ratio | NM |
| Price/Sales | 14.28 |
| Price/Book | 3.38 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| RPRXRepros Therapeutics ... | +0.68 | +4.30% |
| ACRXAcelRx Pharmaceutica... | +0.41 | +5.50% |
| THLDThreshold Pharmaceut... | -0.09 | -1.60% |
| NAVBNavidea Biopharmaceu... | -0.06 | -2.40% |
Data as of 4:01pm ET, 05/24/2013
Financials
| Next reporting date | August 6, 2013 |
| EPS forecast (this quarter) | -$0.11 |
| Annual revenue (last year) | $17.5M |
| Annual profit (last year) | -$22.9M |
| Net profit margin | -130.71% |
Profile
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer, CFO & Director Vijay B. Samant, MBA |
Senior Vice President- Clinical Development Richard T. Kenney, MD |
Corporate headquarters San Diego, California |
Forecasts
